The authors conducted a Phase I trial in 36 patients with hepatocellular carcinoma who were given therapeutic C/EBPα saRNA (MTL-CEBPA) as either neoadjuvant or adjuvant treatment. MTL-CEBPA treatment in those patients caused a marked decrease in peripheral blood monocytic myeloid-derived suppressor cell numbers.
[Clinical Cancer Research]
7992332
{7992332:CF4H3GBW}
apa
50
1
165862
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
